Proliferative potential of T-cell lymphocytes from gliomas.

[1]  A. Maleci,et al.  Modulation of immune function by glioma. , 1992, Immunology today.

[2]  T. Roszman,et al.  Modulation of T-cell function by gliomas. , 1991, Immunology today.

[3]  T. Roszman,et al.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors. , 1990, The Journal of clinical investigation.

[4]  H. Abe,et al.  Isolation and in vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes. , 1988, Journal of neurosurgery.

[5]  N. Mehra,et al.  Imbalances in T cell subpopulations in human gliomas. , 1988, Journal of neurosurgery.

[6]  T. Roszman,et al.  Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. , 1987, Journal of neurosurgery.

[7]  T. Roszman,et al.  Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. , 1987, Journal of the National Cancer Institute.

[8]  T. Roszman,et al.  Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. , 1984, Journal of immunology.

[9]  T. Roszman,et al.  Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. , 1980, Clinical and experimental immunology.

[10]  T. Roszman,et al.  Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. , 1977, Clinical and experimental immunology.

[11]  R. Merchant,et al.  Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro , 2004, Cancer Immunology, Immunotherapy.